PYC Therapeutics (ASX:PYC) Receives Approval to Begin Human Trials for PKD Treatment
PYC Therapeutics (ASX:PYC) receives regulatory approval to commence human trials for its PKD drug candidate, PYC-003.
Category: Healthcare
Radiopharm Theranostics (ASX:RAD) Reports Successful Detection of Brain Metastases with RAD 101
Radiopharm Theranostics (ASX:RAD) announces successful clinical trial results for RAD 101 in detecting brain metastases, advancing their oncology portfolio.
Mayne Pharma Group Limited (ASX:MYX) Announces 1H FY25 Market Update
Mayne Pharma (ASX:MYX) expects 12-14% revenue growth and a 275-300% EBITDA increase for 1H FY25, driven by key sectors.
Ansell Limited (ASX:ANN) Announces Half Year Results and Interim Dividend
Ansell Limited (ASX:ANN) reports a 29.9% revenue increase for H1 and announces an interim dividend of 22.20 US cents per share.
Neuren Pharmaceuticals (ASX:NEU) Receives Priority Review Voucher Sale Proceeds
Neuren Pharmaceuticals (ASX:NEU) receives one-third of proceeds from Priority Review Voucher sale, boosting its financial position.
Nyrada Inc (ASX:NYR) Initiates Phase Ia Clinical Trial
Nyrada Inc (ASX:NYR) has commenced its Phase Ia clinical trial for NYR-BI03, following HREC approval.
Sigma Healthcare Limited (ASX:SIG) Upgrades FY25 EBIT Guidance
Sigma Healthcare (ASX:SIG) upgrades its FY25 EBIT guidance to $64-$70 million, driven by improved operational performance and strong contract execution.
Acrux Limited (ASX:ACR) CEO Michael Kotsanis to Retire
Acrux Limited (ASX:ACR) CEO Michael Kotsanis announces retirement, initiating search for a successor to ensure a smooth transition.
Actinogen Medical (ASX:ACW) Publishes Clinical Pharmacology Study on Xanamem
Actinogen Medical (ASX:ACW) publishes study validating the 10 mg dose of Xanamem for CNS disease treatment, supporting ongoing clinical trials.
Visionflex Group Limited (ASX:VFX) Updates Financing Facilities
Visionflex Group (ASX:VFX) updates its financing facilities and available funding for Q4 2024.